As the grandest medical device exhibition in the Middle East, MEDLAB Middle East concluded today. At the exhibition site, professionals from around the world gathered to discuss the development trends of medical technology. At this year’s Dubai exhibition, Tellgen presented multi-scenario solutions including chemiluminescence platform, molecular detection platform, biochemical series products, POCT platform, etc. Tellgen solemnly launched its new product, the small chemiluminescence immunoassay analyzer TESMI i50.
New Product Launch
As a small chemiluminescence analyzer launched by Tellgen to meet market demands, TESMI i50 attracted a lot of customers’ attention as soon as it debuted in the overseas market. Visitors gained an in-depth understanding of the technical features and application advantages of TESMI i50 through communication with the Tellgen team.
TESMI i50 adopts Tellgen’s chemiluminescence platform technology using acridinium ester direct labeling chemiluminescence method. The instrument can run more than 70 items, including thyroid function, cardiac markers, tumor markers, sex hormones, etc.
- Small instrument size, modular design for easy maintenance, low-cost maintenance without engineers, high cost-effectiveness.
- 20-test reagent kit design meets the low sample volume requirements of small hospitals and emergency laboratories in large hospitals.
- 24 sample positions, 10 reagent positions.
Tellgen’s partners took advantage of this exhibition to visit Tellgen’s booth, where we fully demonstrated Tellgen’s innovative technologies and latest solutions, exchanged and discussed the latest industry dynamics and market development trends. At the same time, through communication with customers, we collected a wealth of valuable feedback, providing direction for future product research and development.
This participation not only strengthened our relationship with partners, but also brought us new cooperation opportunities. We have gained the favor and attention of many professionals and visitors, deepening their understanding and trust in Tellgen’s products, and exploring more cooperation possibilities.
We look forward to cooperating with partners and customers from more countries in the future to jointly create a new future for Tellgen Life in the overseas in vitro diagnostics industry! Thank you, MedLab Middle East 2024, and we look forward to reuniting at next year’s exhibition!